Patterns of chemotherapy administration in patients with intermediate-grade non-hodgkin's lymphoma

ONCOLOGY

Volumn 15, Issue 10, 2001, Pages 1296-1306

  Picozzi, Vincent J ^a   Pohlman, Brad L ^b   Morrison, Vicki A ^c   Lawless, Grant D ^d   Lee, Martin W ^e   Kerr, Robert O ^f   Ford, Jon M ^g   Delgado, David J ^g   Fridman, Moshe ^h   Carter, William B ^g  

^a VIRGINIA MASON MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Highmark Blue Cross Blue Shield   (United States)

^e PARK NICOLLET INSTITUTE   (United States)

^f Southwest Regional Cancer Center   (United States)

^g AMGEN INC   (United States)

^h AMF Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHOP PROTOCOL; CYCLOPHOSPHAMIDE; DOXORUBICIN; GROWTH PROMOTOR; LACTATE DEHYDROGENASE; MCOP PROTOCOL; MITOXANTRONE; PREDNISOLONE; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; ENZYMOLOGY; FEMALE; HOSPITALIZATION; HUMAN; MALE; MIDDLE AGED; NEUTROPENIA; NONHODGKIN LYMPHOMA; REFERENCE VALUE; RETROSPECTIVE STUDY; TIME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; GROWTH SUBSTANCES; HUMANS; L-LACTATE DEHYDROGENASE; LYMPHOMA, INTERMEDIATE-GRADE; MALE; MIDDLE AGED; MITOXANTRONE; NEUTROPENIA; PREDNISOLONE; PREDNISONE; REFERENCE VALUES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; VINCRISTINE;

EID: 0035489245     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Cancer Facts & Figures 2001. Atlanta, American Cancer Society, 2001.
2. Wingo PA: Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst 91(8):675-690, 1999.
3. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329(14):987-994, 1993.
4. National Comprehensive Cancer Network: NCCN preliminary non-Hodgkin's lymphoma practice guidelines. Oncology 11(11A):281, 1997.
5. DeVita VT Jr, Hellman S, Rosenberg SA: Cancer Principles and Practice of Oncology, 5th ed. Philadelphia, Lippincott-Raven, 1997.
6. McKelvey EM, Gottlieb JA, Wilson HE, et al: Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Conor 38:1484-1493, 1976.
7. Coltman CA: CHOP is curative in 30% of patients with large-cell lymphoma: A 12-year Southwest Oncology Group follow-up, in Skarin A (ed): Update on Treatment for Diffuse Large Cell Lymphoma, pp 71-77. New York, Park Row, 1986.
8. Coltman CA, Dahlberg S, Jones SE: Southwest Oncology Group studies in diffuse large-cell lymphoma: A subset analysis, in Kimura K (ed): Cancer Chemotherapy, pp 194-202. Tokyo, Excerpta Medica, 1988.
9. Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328(14):1002-1006, 1993.
10. Sonneveld P, de Ridder M, van der Lelie H, et al: Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP vs CNOP chemotherapy. J Clin Oncol 13(10):2530-2539, 1995.
11. Pavlovsky S, Santarelli MT, Erazo A, et al: Results of a randomized study of previously untreated intermediate- and high-grade lymphoma using CHOP vs CNOP. Ann Oncol 3:205-209, 1992.
12. Luce JK, Gamble JF, Wilson HE, et al: Combined cyclophosphamide, vincristine, prednisone therapy of malignant lymphoma. Cancer 28(2):306-317, 1971.
13. Bagley CM Jr, Devita VT Jr, Berard CW, et al: Advanced lymphosarcoma: Intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone. Ann Intern Med 76:227-234, 1972.
14. Lenhard RE Jr, Ezdinli EZ, Costello W, et al: Treatment of histiocycltic and mixed lymphomas. Cancer 42:41-52, 1978.
15. Bjorkholm M, Osby E, Hagberg H, et al: Randomized trial of r-metHu granulocyte colony-stimulating factor (G-CSF) as adjunct to CHOP or CNOP treatment of elderly patients with aggressive non-Hodgkin's lymphoma (abstract 2665). Blood 94:599a, 1999.
16. Kwak LW, Halpern J, Olshen RA, et al: Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis. J Clin Oncol 8:963-977, 1990.
17. Epelbaum R, Haim N, Ben-Shahar M, et al: Dose intensity for CHOP chemotherapy in diffuse aggressive large cell lymphoma. Isr J Med Sci 24:533-538, 1988.
18. Meyer RM, Browman GP, Samosh ML, et al: Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol 13(9):2386-2393, 1995.
19. Tirelli U, Errante D, Van Glabbeke M, et al: CHOP is the standard regimen in patients > 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: Results of a randomized study of the European Organization for Research and treatment of Cancer Lymphoma Cooperative Study. J Clin Oncol 16(1):27-34, 1998.
20. Pizzo PA, Hathorn JW, Hiemenz J, et al: A randomized trial comparing ceftaxidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 315:552-558, 1986.